Physician profile
Karol Bowens
NPI 1083798284
$3,753.24
in general payments reported to CMS, 2019-2025
30 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $397 · 2021: $578 · 2022: $437 · 2023: $847 · 2024: $505 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Travel and Lodging: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.95 |
| Travel and Lodging | $258.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,005.72 | 2019-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $442.98 | 2023-2025 | Myfembree |
| Applied Medical Resources Corporation | $300.18 | 2023 | Gelpoint V-Path |
| Exeltis, USA INC. | $251.48 | 2022-2025 | Slynd |
| Organon LLC | $250.90 | 2021-2024 | Nexplanon |
| Mayne Pharma Commercial LLC | $206.68 | 2022-2025 | |
| Evofem Biosciences, INC. | $194.79 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $175.80 | 2019-2024 | Gardasil 9, Gardasil |
| Astellas Pharma US INC | $138.12 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $124.08 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $86.33 | 2022 | |
| Myovant Sciences INC. | $60.91 | 2021-2022 | |
| Smith+Nephew, INC. | $47.75 | 2023-2025 | Pico |
| Therapeuticsmd, INC. | $47.50 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $43.86 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $41.64 | 2025 | Femlyv |
| Allergan, INC. | $38.14 | 2019 | |
| Roche Diagnostics Corporation | $37.70 | 2019 | |
| Baxter Healthcare | $34.38 | 2024 | Perclot |
| Shield Therapeutics INC | $32.91 | 2024 | |
| Biom'Up France Sas | $24.44 | 2020 | |
| Dexcom, INC. | $22.58 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $22.43 | 2023 | |
| Sage Therapeutics, LLC | $21.02 | 2019 | |
| Glaxosmithkline, LLC. | $20.86 | 2024 | Rotarix, Pediarix, Bexsero |
| Boston Scientific Corporation | $20.11 | 2019 | |
| Agile Therapeutics, INC. | $17.24 | 2022 | |
| Cranial Technologies, INC | $14.98 | 2023 | Doc Band |
| Viiv Healthcare Company | $14.98 | 2019 | |
| Coopersurgical, INC. | $12.75 | 2023 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karol Bowens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.